<DOC>
	<DOCNO>NCT01736449</DOCNO>
	<brief_summary>A pterygium fibrovascular growth originate conjunctiva grows onto surface cornea . Frequently , pterygia recur even surgical resection . Bevacizumab inhibitor angiogenesis , need recurrent growth . The use bevacizumab poorly understood inhibit pterygium growth . The objective study compare effect wound heal recurrence rate postoperative bevacizumab versus pterygium excision alone .</brief_summary>
	<brief_title>Role Sub-Conjunctival Bevacizumab Post Pterygium Excision Management</brief_title>
	<detailed_description>This prospective trial . Thirty-one patient primary pterygium least 2 mm size without previous ocular surgery include . Outcome measure include best correct visual acuity , intraocular pressure , recurrence , sight threaten complication two week , two month , six month postoperatively .</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient 18 year age old primary pterygium extend least 2 mm past limbus history glaucoma previous ocular surgery steroidresponse glaucoma previous myocardial infarct bleed disorder pregnancy lack patient cooperation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>pterygium</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>recurrence pterygium</keyword>
</DOC>